News

March 13, 2019

Engage Therapeutics to Present Phase 2b Open Label Run-in Data from StATES Trial of Staccato Alprazolam at 2019 American Academy of Neurology Annual Meeting

SUMMIT, N.J., March 11, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience […]
February 11, 2019

How Engage Therapeutics Is Improving Life With Epilepsy

International Epilepsy Day is here! With individuals and organizations sharing stories of taking action, we thought we’d take the opportunity to reflect on what the team […]
December 3, 2018

Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion

On December, 3, 2018, Engage Therapeutics announced at the American Epilepsy Society’s Annual Meeting the successful completion of the open label portion of the StATES (Staccato […]
October 22, 2018

Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research

Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research: Health Care 50 | Time.com
September 14, 2018

Interview with Greg Mayes of Engage Therapeutics

Greg Mayes is the president, CEO, and founder of Engage Therapeutics, founded in 2017 to clinically develop and progress a product called staccato alprazolam, which had […]
September 14, 2018

What The After Party Gets Right About Epilepsy

“When an aspiring rapper goes viral for all the wrong reasons, he thinks his career is over. But when his best friend gets them into a […]
August 13, 2018

A FACES-Inspired Clinical Trial – Engage Therapeutics CEO, Greg Mayes

Read the article by Greg Mayes, Engage Therapeutics CEO, in FACES Annual Newsletter 2018: View the full newsletter here (PDF)
June 27, 2018

Engage Therapeutics CEO, Greg Mayes, makes opening remarks to Clinical Investigators at the StATES Investigator Meeting. New Orleans, LA – June 8, 2018

Engage Therapeutics CEO, Greg Mayes, makes opening remarks to Clinical Investigators at the StATES Investigator Meeting. New Orleans, LA – June 8, 2018
May 18, 2018

STACCATO® ALPRAZOLAM

G. Mayes CEO, Engage Therapeutics, Summit, NJ, United States Staccato Alprazolam (STAP-001) is a single-use, hand-held, drug-device combination product that provides rapid systemic delivery by inhalation […]
April 30, 2018

Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato® Alprazolam

Peachtree BioResearch Solutions to Execute Multi-Center Trial SUMMIT, N.J. – April XX, 2018 – Engage Therapeutics, Inc., today announced dosing of the first patient in its […]